120 related articles for article (PubMed ID: 26394271)
21. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
22. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
Rheumatology (Oxford); 2007 Apr; 46(4):695-8. PubMed ID: 17158212
[TBL] [Abstract][Full Text] [Related]
23. Tumor necrosis factor blockade and the risk of viral infection.
Kim SY; Solomon DH
Nat Rev Rheumatol; 2010 Mar; 6(3):165-74. PubMed ID: 20142812
[TBL] [Abstract][Full Text] [Related]
24. Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data.
Scrivo R; Armignacco O
Int J Rheum Dis; 2014 Sep; 17(7):716-24. PubMed ID: 24725559
[TBL] [Abstract][Full Text] [Related]
25. Golimumab, the newest TNF-α blocker, comes of age.
Papagoras C; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2015; 33(4):570-7. PubMed ID: 25602858
[TBL] [Abstract][Full Text] [Related]
26. [Risk of infection through use of selective immunomodulating drugs for rheumatoid arthritis].
Harboe E; Damås JK; Omdal R; Frøland SS; Sjursen H
Tidsskr Nor Laegeforen; 2012 Sep; 132(16):1867-71. PubMed ID: 22986971
[TBL] [Abstract][Full Text] [Related]
27. Varicella zoster virus infection in patients taking the TNF-alpha inhibitor, etanercept: coincidence or causal?
Izumi A
Hawaii Med J; 2009 Dec; 68(11):277-8. PubMed ID: 20034255
[TBL] [Abstract][Full Text] [Related]
28. Advances in the treatment of varicella-zoster virus infections.
Andrei G; Snoeck R
Adv Pharmacol; 2013; 67():107-68. PubMed ID: 23886000
[TBL] [Abstract][Full Text] [Related]
29. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment.
Nordgaard-Lassen I; Dahlerup JF; Belard E; Gerstoft J; Kjeldsen J; Kragballe K; Ravn P; Sørensen IJ; Theede K; Tjellesen L;
Dan Med J; 2012 Jul; 59(7):C4480. PubMed ID: 22759856
[TBL] [Abstract][Full Text] [Related]
30. Study of the natural course and specific immunity after herpes zoster in patients with rheumatoid arthritis receiving biologic DMARDs.
Thomas K; Sfikakis PP; Boumpas D; Boki K; Vassilopoulos D
Mediterr J Rheumatol; 2017 Sep; 28(3):164-168. PubMed ID: 32185277
[TBL] [Abstract][Full Text] [Related]
31. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Raaschou P; Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
[TBL] [Abstract][Full Text] [Related]
32. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
[TBL] [Abstract][Full Text] [Related]
33. Purulent pericarditis in a patient with rheumatoid arthritis treated with etanercept and methotrexate.
Sweet DD; Isac G; Morrison B; Fenwick J; Dhingra V
CJEM; 2007 Jan; 9(1):40-2. PubMed ID: 17391602
[TBL] [Abstract][Full Text] [Related]
34. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
[TBL] [Abstract][Full Text] [Related]
35. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
Kapetanovic MC; Saxne T; Nilsson JA; Geborek P
Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
[TBL] [Abstract][Full Text] [Related]
36. Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
van Dartel SA; Fransen J; Kievit W; Dutmer EA; Brus HL; Houtman NM; van de Laar MA; van Riel PL
Rheumatology (Oxford); 2013 Jun; 52(6):1052-7. PubMed ID: 23365147
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis as a mechanism of action of tumor necrosis factor antagonists in rheumatoid arthritis.
Makrygiannakis D; Catrina AI
J Rheumatol; 2012 Apr; 39(4):679-85. PubMed ID: 22422498
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
[TBL] [Abstract][Full Text] [Related]
39. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
König C; Kleber M; Reinhardt H; Knop S; Wäsch R; Engelhardt M
Ann Hematol; 2014 Mar; 93(3):479-84. PubMed ID: 24318541
[TBL] [Abstract][Full Text] [Related]
40. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
